150+ Speakers

The World Antimicrobial Resistance Congress agenda will feature over 150 speakers across four streams. Hospitals, investors, government employees, regulators, international organizations, funding agencies and innovative solution providers will be discussing the most pressing and contentious areas of combating antimicrobial resistance.

2018 Key Speakers

Tyler Merkeley

Tyler Merkely
Project Officer, DHHS , Program Manager, CARB-X

Jeremy Knox

Jeremy Knox
Policy and Advocacy Lead, Drug-Resistant Infections Programme
Wellcome Trust

Jeff Stein

Jeff Stein
Chief Executive Officer
Cidara Therapeutics

Dmitri Iarikov

Dmitri Iarikov
Deputy Director in the Division of Anti-Infective Products
FDA

Joshua Resnick

Joshua Resnic
Venture Partner
SV Health Investors

Dan Weschler

Dan Wechsler
President & Chief Executive Officer
Melinta Therapeutics

Larry Kerr

Larry Kerr
Director, Office of Pandemic and Emerging Threats, U.S. DHHS , Co-Chair,  TATFAR

Paul Auwaerter

Paul Auwaerter 
President 
Infectious Diseases Society of America (IDSA)

Silas Holland

Silas Holland
Director of Infectious Diseases Policy
Merck

Christine Ardal

Christine Ardal
Senior Advisor, Norwegian Institute of Public Health , Co-Lead, DRIVE-AB

Daniel Knecht

Daniel Knecht
Vice President of Clinical Strategy & Policy
Aetna

Michael Dudley

Michael Dudley
Senior Vice President and Chief Scientific Officer
The Medicines Company

Debra Goff

Debra Goff
Infectious Diseases Specialist, The Ohio State University Wexner Medical Center , Clinical Associate Professor, The Ohio State University College of Pharmacy

Dmitri Iarikov

Peter Jackson
Director
AMR Centre

Blake Wise

Blake Wise
Chief Executive Officer
Achaogen

 

All 2018 Speakers:

Dirar Abdullah, Head, Adult Critical Care Services, Chair, Antibiotic Committee and Antibiotic Stewardship Program, Prime Hospital- Dubai

Dirar Abdullah at World Anti-Microbial Resistance Congress 2018

Nicholas Adomakoh, Global Medical Affairs Lead for Anti-infectives, Sandoz International GmbH

Brian Michael Aldridge, Clinical Professor, Department of Veterinary Clinical Medicine, University of Illinois College of Veterinary Medicine

Brian Michael Aldridge at World Anti-Microbial Resistance Congress 2018

Javad Aman, Chief Executive Officer, Integrated Biotherapeutics

Javad Aman at World Anti-Microbial Resistance Congress 2018

Christine Årdal, Senior Advisor, Norwegian Institute of Public Health

Paul Auwaerter, President, Infectious Diseases Society of America IDSA

Paul Auwaerter at World Anti-Microbial Resistance Congress 2018

Thierry Bernardi, CEO, Biofilm Pharma

Susan Casey Bleasdale, Medical Director Infection Prevention & Control and Antimicrobial Stewardship, University of Illinois Hospital & Health Sciences System

Mark Bradley, Director, EPSRC Proteus IRC

Gabrielle Breugelmans, Director of Research, Access to Medicine Foundation

Gabrielle Breugelmans at World Anti-Microbial Resistance Congress 2018

Colin Broom, Chief Executive Officer, Nabriva Therapeutics

Nancy Caralla, Founding President and Executive Director, C Diff Foundation

Nancy Caralla at World Anti-Microbial Resistance Congress 2018

Cornelius J. (Neil) Clancy, Associate Professor of Medicine, Infectious Diseases Division, and Director, Mycology Program, University of Pittsburgh

Timothy Cooke, Chief Executive Officer, NovaDigm Therapeutics

Timothy Cooke at World Anti-Microbial Resistance Congress 2018

Sanjeet Dadwal, Associate Clinical Professor Head of Antimicrobial Stewardship Program, City of Hope

Sanjeet Dadwal at World Anti-Microbial Resistance Congress 2018

Glenn Dale, Head of Early Development, Antimicrobials, Polyphor Ltd

Glenn Dale at World Anti-Microbial Resistance Congress 2018

Gregory Daniel, Deputy Director, Duke University

Gregory Daniel at World Anti-Microbial Resistance Congress 2018

Lisa Davidson, Medical Director, Antimicrobial Support Network, Atrium Health

Kev Dhaliwal, Team Leader, EPSRC Proteus IRC

Kev Dhaliwal at World Anti-Microbial Resistance Congress 2018

Enea Di Domenico, Clinical Pathology and Microbiology, Istituti Fisioterapici Ospitalieri

Enea Di Domenico at World Anti-Microbial Resistance Congress 2018

Sarah Doernberg, Associate Professor, University of California, San Francisco

Sarah Doernberg at World Anti-Microbial Resistance Congress 2018

Michael Dudley, Senior Vice President, Chief Scientific Officer, Head Infectious Disease Innovation, The Medicines Company

Barry Eisenstein, Chair, Scientific Advisory Board, CARB-X

Anthony Emeribe, Professor, University of Calibar, Nigeria and Member, WHO Strategic Advisory Group of Experts on In-Vitro Diagnostics (SAGE-IVD)

Anthony Emeribe at World Anti-Microbial Resistance Congress 2018

Mark Engel, CEO, Phagelux

Sandy Estrada, Director Clinical Affairs, T2 Biosystems Inc

Olivier Favre Bulle, Founder and Consultant in Drug Development and Business Strategy, 3Biotech

Olivier Favre Bulle at World Anti-Microbial Resistance Congress 2018

Greg Frank, Director, Infectious Disease Policy, BIO

Greg Frank at World Anti-Microbial Resistance Congress 2018

Kuntal Ganguly, Lead Scientist, Venus Remedies Limited

Paul Garofolo, Chief Executive Officer, Locus Biosciences

Paul Garofolo at World Anti-Microbial Resistance Congress 2018

Steven Gilman, Chief Executive Officer, Contrafect Corporation

Steven Gilman at World Anti-Microbial Resistance Congress 2018

Marc Gitzinger, Chief Executive Officer And Co-Founder, Bioversys

Marc Gitzinger at World Anti-Microbial Resistance Congress 2018

Debra Goff, Infectious Diseases Specialist,The Ohio State University Wexner Medical Center Clinical Associate Pr, Ohio State University Medical Center

Rana Hamdy, Director, Antimicrobial Stewardship Program, Children's National Health System

Rana Hamdy at World Anti-Microbial Resistance Congress 2018

Benjamin Hammer, Co-leader of the Antimicrobial Stewardship Program, Children's National Health System

Benjamin Hammer at World Anti-Microbial Resistance Congress 2018

Janet Hammond, Vice President Infectious Diseases, AbbVie

Janet Hammond at World Anti-Microbial Resistance Congress 2018

Elizabeth Hermsen, Head, Global Antimicrobial Stewardship, Merck & Co., Inc.

Silas Holland, Director of Infectious Disease Policy, Merck & Co

Silas Holland at World Anti-Microbial Resistance Congress 2018

Chris Houchens, Health Scientist, BARDA

David Huang, Chief Medical Officer, Motif Bio

Dmitri Iarikov, Deputy Director in the Division of Anti-Infective Products, FDA

Dmitri Iarikov at World Anti-Microbial Resistance Congress 2018

Peter Jackson, CEO, The AMR Centre UK

Amanda Jezek, Senior VP, Public Policy and Government Relations, Infectious Diseases Society of America

Amanda Jezek at World Anti-Microbial Resistance Congress 2018

Eugean Jiwanmall, Senior Research Analyst, Technology Evaluation & Medical Policy, Independence Blue Cross

Eugean Jiwanmall at World Anti-Microbial Resistance Congress 2018

Lee Jones, Founder, President and Chief Executive Officer, Rebiotix, Inc.

Lee Jones at World Anti-Microbial Resistance Congress 2018

Mark Jones, Head of Clinical Development and Preclinical Development, Basilea Pharmaceutica Ltd

Mark Jones at World Anti-Microbial Resistance Congress 2018

Sanjay Kakkar, CEO, Peptilogics

Patrick Keenan, Managing Director, Prevail Partners

Larry Kerr, Director, Office of Pandemic and Emerging Threats, Office of Global Affairs, Department of Health and Human Services

Barbara Kerstiens, Deputy Head of Unit, Fighting Infectious Diseases and Advancing Public Health Research and Innovatio, European Commission

Wes Kim, Senior Officer, The Pew Charitable Trusts

Wes Kim at World Anti-Microbial Resistance Congress 2018

Eili Klein, Fellow, Center for Disease Dynamics Economics & Policy

Daniel Knecht, Vice President, Clinical Strategy & Policy, Aetna

Jane Knisely, Program Officer, Bacteriology and Mycology Branch, NIAID, NIAID, NIH & University of Kansas

Jeremy Knox, Policy and Advocacy Lead, Drug-Resistant Infections Programme, Wellcome Trust

Jeremy Knox at World Anti-Microbial Resistance Congress 2018

John Kokai-Kun, Vice President of Non-Clinical Affairs, Synthetic Biologics Inc

Kerry Laplante, Professor, University Of Rhode Island

Jean-Philippe Lavigne, Clinical Microbiologist, Centre Hospitalier Régional Universitaire De Nimes

Jean-Philippe Lavigne at World Anti-Microbial Resistance Congress 2018

Colm Leonard, Consultant Clinical Advisor, NICE

Colm Leonard at World Anti-Microbial Resistance Congress 2018

Tom Lowery, Chief Scientific Officer, T2 Biosystems Inc

Gregory Mario, Chief Executive Officer, T.A.X.I.S. Pharmaceuticals Inc

Jill Massey, Senior Vice President, Medical Affairs, Melinta Therapeutics Inc

Pascal Mayer, Chief Executive Officer, Alphanosos

Tyler Merkeley, Program Manager, CARB-X

Mary Millard, M. Ed, Patient Advocate, Sepsis Survivor

Donald Moir, Chief Scientific Officer, Microbiotix Inc

Donald Moir at World Anti-Microbial Resistance Congress 2018

Mary Motyl, Director of Clinical Microbiology, Merck & Co

Steve Nagler, Executive Director, MedPro Investors LLC

Steve Nagler at World Anti-Microbial Resistance Congress 2018

Kevin Outterson, Executive Director, CARB-X

Kevin Outterson at World Anti-Microbial Resistance Congress 2018

Jean-Pierre Paccaud, Director, Business Development and Corporate Strategy, Global Antibiotic Research and Development Partnership (GARDP)

Jean-Pierre Paccaud at World Anti-Microbial Resistance Congress 2018

Brandon Palermo, CMO at ILUM Health Solutions and Executive Director and CMO, Merck & Co

Brandon Palermo at World Anti-Microbial Resistance Congress 2018

Rosanna Peeling, Director, International Diagnostics Centre and Chair and Professor of Diagnostic Research, London School of Hygiene and Tropical Medicine

Rosanna Peeling at World Anti-Microbial Resistance Congress 2018

Manos Perros, President & CEO, Entasis Therapeutics

Marie Petit, Coordinator, The Beam Alliance

Marie Petit at World Anti-Microbial Resistance Congress 2018

Yannick Pletan, Acting Chief Medical Officer, Biofilm Pharma

Yannick Pletan at World Anti-Microbial Resistance Congress 2018

Joshua Resnick, Partner, SV Health Investors

Michael Salter, R&D Facilitator, A.B. Agri

Robert Sambursky, Founder, Chief Executive Officer, and President, Rapid Pathogen Screening, Inc (RPS)

Rangarajan Sampath, Chief Scientific Officer, FIND

Rangarajan Sampath at World Anti-Microbial Resistance Congress 2018

Harshika Sarbajna, Global Head, Anti-infectives, Sandoz International GmbH

Monika Schneider, Research Associate, Margolis Center for Health Policy, Duke University

Ted Schroeder, Chief Executive Officer, Nabriva Therapeutics

Ted Schroeder at World Anti-Microbial Resistance Congress 2018

Rajeev Sehgal, Director of Informatics, BD Life Sciences

Ed Septimus, Medical Director of Infection Prevention and Epidemiology, H.C.A.

Ribhi Shawar, Branch Chief, Division of Microbiology, CDRH OIVD FDA

Rick Sibbel, Executive Director and Technical Services, Merck Animal Health

Trish Simner, Director of Bacteriology and Parasitology, Division of Medical Microbiology, Johns Hopkins Medical Institutions

Henry Skinner, Senior Vice President, Tekla Capital Management

Henry Skinner at World Anti-Microbial Resistance Congress 2018

Jeff Stein, President and Chief Executive Officer, Cidara Therapeutics

Jeff Stein at World Anti-Microbial Resistance Congress 2018

Scott Stibitz, Center for Biologics Evaluation and Research (CBER), FDA

Scott Stibitz at World Anti-Microbial Resistance Congress 2018

Leslie Tari, Vice President, Discovery, Cidara Therapeutics

Leslie Tari at World Anti-Microbial Resistance Congress 2018

Pamela Tenaerts, Executive Director, Clinical Trials Transformation Initiative

Pamela Tenaerts at World Anti-Microbial Resistance Congress 2018

Keiko Tone, VP Market Access, Shionogi Limited

Keiko Tone at World Anti-Microbial Resistance Congress 2018

Jennifer Townsend, Director of Antimicrobial Stewardship program, Johns Hopkins Bayview Medical Center

Ephraim Tsalik, Associate Professor of Medicine Division of Infectious Diseases, Duke University Medical Center

Ephraim Tsalik at World Anti-Microbial Resistance Congress 2018

Brian Tse, Health Scientist, HHS/BARDA

Fred Turner, Founder & CEO, Shield Diagnostics

Evan Tzanis, Senior Vice President, Chief Development Officer, Paratek Pharmaceuticals

Nick Van Hise, Infectious Diseases Clinical Pharmacy Specialist, Research Coordinator, Metro Infectious Disease Consultants

Nick Van Hise at World Anti-Microbial Resistance Congress 2018

Marijn Verhoef, Engagement Manager, Access to Medicine Foundation

Richard Vickers, SVP and CSO, Anti-Infectives, Summit Therapeutics

Richard Vickers at World Anti-Microbial Resistance Congress 2018

David Visi, Senior Associate, Antibiotic Resistance Project, The Pew Charitable Trusts

Daniel Wechsler, Chief Executive Officer, Melinta Therapeutics Inc

Blake Wise, Chief Executive Officer, Achaogen

Zachary Zimmerman, CEO, Forge Therapeutics

If you are interested in speaking at our 2018 conference, contact Claire Murphy at +1 646 619 1784 or claire.murphy@terrapinn.com now!

 

SIGN UP FOR EVENT UPDATES